Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 6
Submit an article Journal homepage
334
Views
9
CrossRef citations to date
0
Altmetric
Original Articles

A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia

Jorge J. CastilloBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; ;Department of Medicine, Harvard Medical School, Boston, MA, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-9490-7532View further author information
ORCID Icon,
Gilad ItchakiBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; ;Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel; ORCID Iconhttp://orcid.org/0000-0002-9064-8139View further author information
ORCID Icon,
Joshua N. GustineBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; ;Department of Medicine, Boston University School of Medicine, Boston, MA, USAORCID Iconhttp://orcid.org/0000-0001-6717-7669View further author information
ORCID Icon,
Kirsten MeidBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; View further author information
,
Catherine A. FlynnBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; View further author information
,
Maria G. DemosBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; View further author information
,
Maria L. GuerreraBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; View further author information
,
Cristina JimenezBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; View further author information
,
Amanda KofidesBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; View further author information
,
Xia LiuBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; View further author information
,
Manit MunshiBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; View further author information
,
Nicholas TsakmaklisBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; View further author information
,
Christopher J. PattersonBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; View further author information
,
Lian XuBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; View further author information
,
Guang YangBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; ORCID Iconhttp://orcid.org/0000-0003-3049-4200View further author information
ORCID Icon,
Zachary R. HunterBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; ORCID Iconhttp://orcid.org/0000-0002-1689-1691View further author information
ORCID Icon &
Steven P. TreonBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA; ;Department of Medicine, Harvard Medical School, Boston, MA, USA; ORCID Iconhttp://orcid.org/0000-0001-6393-6154View further author information
ORCID Icon show all
Pages 1388-1394 | Received 19 Dec 2019, Accepted 16 Jan 2020, Published online: 29 Jan 2020

References

  • Sekhar J, Sanfilippo K, Zhang Q, et al. Waldenstrom macroglobulinemia: a surveillance, epidemiology, and end results database review from 1988 to 2005. Leuk Lymphoma. 2012;53(8):1625–1626.
  • Swerdlow SH, Cook, JR, Sohani AR, et al. Lymphoplasmacytic lymphoma. In: Swerdlow SH, editor. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon, France: IARC; 2017. p. 232–235.
  • Cao X, Medeiros LJ, Xia Y, et al. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma. 2016;57(5):1104–1113.
  • King RL, Gonsalves WI, Ansell SM, et al. Lymphoplasmacytic lymphoma with a non-IgM paraprotein shows clinical and pathologic heterogeneity and may harbor MYD88 L265P mutations. Am J Clin Pathol. 2016;145(6):843–851.
  • Varettoni M, Boveri E, Zibellini S, et al. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: a multicentric study of the Rete Ematologica Lombarda (REL) network. Am J Hematol. 2019;94(11):1193–1199.
  • Kang J, Hong JY, Suh C. Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience. Blood Res. 2018;53(3):189–197.
  • Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171–176.
  • Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637–1646.
  • Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367(9):826–833.
  • Xu L, Hunter ZR, Tsakmaklis N, et al. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol. 2016;172(5):735–744.
  • Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051–2058.
  • Castillo JJ, Ghobrial IM, Treon SP. Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leuk Lymphoma. 2016;57(11):2699–2701.
  • Jimenez C, Sebastian E, Chillon MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom’s macroglobulinemia. Leukemia. 2013;27(8):1722–1728.
  • Mori N, Ohwashi M, Yoshinaga K, et al. L265P mutation of the MYD88 gene is frequent in Waldenstrom’s macroglobulinemia and its absence in myeloma. PLoS One. 2013;8(11):e80088.
  • Treon SP, Gustine J, Xu L, et al. MYD88 wild-type Waldenstrom macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018;180(3):374–380.
  • Gustine J, Meid K, Xu L, et al. To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenstrom Macroglobulinaemia. Br J Haematol. 2017;176(5):822–824.
  • Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, et al. Progression risk stratification of asymptomatic waldenström macroglobulinemia. J Clin Oncol. 2019;37(16):1403–1411.
  • D’Sa S, Kersten MJ, Castillo JJ, et al. Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017;176(5):728–742.
  • Gustine JN, Meid K, Dubeau T, et al. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2017;177(5):717–725.
  • Roberts-Thomson PJ, Shepherd K. Molecular size heterogeneity of immunoglobulins in health and disease. Clin Exp Immunol. 2008;79(3):328–334.
  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Version 1.2020. Waldenström’s macroglobulinemia/lymphoplasmacytic lymphoma. [cited 2020 Jan 5]. Available form: http://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.